56. Behcet disease Clinical trials / Disease details

Clinical trials : 76 / Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100045463	2021-05-01	2021-04-15	Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study	Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study	intestinal Beh?et's disease	One-armed intervention group:adalimumab;	The First Affiliated Hospital, College of Medicine, Zhejiang University	NULL	Recruiting	18	70	Both	One-armed intervention group:30;	Phase 4	China
2	ChiCTR1900027147	2020-01-01	2019-11-02	Efficacy and safety of adalimumab in Behcet's disease-related uveitis	Efficacy and safety of adalimumab in Behcet's disease-related uveitis	Behcet's disease-related uveitis	1:Adalimumab;	State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University	NULL	Pending			Both	1:30;	Phase 4	China
3	EUCTR2017-000845-39-IT (EUCTR)	12/05/2017	08/06/2021	Effectiveness of anti TNFalpha agents in Behcet¿s disease	THE ROLE OF ANTI TNF ALPHA AGENTS IN BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES: MULTICENTER RANDOMIZED CONTROLLED PROSPECTIVE PARALLEL GROUP SINGLE-BLIND TRIAL TO EVALUATE THE 6 MONTH EFFECTIVENESS OF EITHER INFLIXIMAB OR ADALIMUMAB - FARM12LTAT	BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES MedDRA version: 20.0;Level: LLT;Classification code 10004215;Term: Behcets disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER Product Name: HUMIRA Product Code: HUMIRA INN or Proposed INN: ADALIMUMAB Trade Name: INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO Product Name: INFLECTRA Product Code: INFLECTRA INN or Proposed INN: INFLIXIMAB Trade Name: MEDROL - 4 MG COMPRESSE 30 COMPRESSE Product Name: MEDROL INN or Proposed INN: METILPREDNISOLONE Trade Name: SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML Product Name: SOLU MEDROL Product Code: SOLU MEDROL INN or Proposed INN: METILPREDNISOLONE SODIO SUCCINATO Trade Name: SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML Product Name: SOLU MEDROL Product Code: SOLU MEDROL	AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	46	Phase 3	Italy
4	JPRN-UMIN000012469	2013/12/02	02/12/2013	Comparison of Adalimumab and Steroid in Intestinal Behcet's disease	Comparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study	Intestinal Behcet's disease	Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously. Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately	Castle Study Group	NULL	Recruiting	15years-old	Not applicable	Male and Female	50	Not selected	Japan
5	NCT01243671 (ClinicalTrials.gov)	October 2010	17/11/2010	A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease	A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease	Intestinal Behçet's Disease	Biological: Adalimumab	AbbVie (prior sponsor, Abbott)	Eisai Co., Ltd.	Completed	15 Years	N/A	All	20	Phase 3	Japan